Showing results (21-30 of 41) with videos related to
Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2014
A phase I, dose-escalation study of the multitargeted receptor tyrosine kinase inhibitor, golvatinib, in patients with advanced solid tumorsL Rhoda Molife, Emma Jane Dean, Montserrat Blanco-Codesido, et al.Cancer Chemotherapy and Pharmacology|August 6, 2015
Olaparib tablet formulation: effect of food on the pharmacokinetics after oral dosing in patients with advanced solid tumoursRuth Plummer, Helen Swaisland, Karin Leunen, et al.The Journal of Pathology|November 21, 2012
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitorLouise J Barber, Shahneen Sandhu, Lina Chen, et al.Journal of Hematology & Oncology|January 7, 2014
Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumorsL Rhoda Molife, Li Yan, Joanna Vitfell-Rasmussen, et al.British Journal of Clinical Pharmacology|April 1, 2020
Pharmacokinetics and safety of olaparib in patients with advanced solid tumours and mild or moderate hepatic impairmentChristian Rolfo, Nicolas Isambert, Antoine Italiano, et al.Clinical Pharmacokinetics|March 17, 2019
Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal ImpairmentChristian Rolfo, Judith de Vos-Geelen, Nicolas Isambert, et al.The Lancet. Oncology|December 29, 2009
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort studyDavid Olmos, Sophie Postel-Vinay, L Rhoda Molife, et al.European Journal of Cancer (Oxford, England : 1990)|February 20, 2017
Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unitDionysis Papadatos-Pastos, Desam Roda, Maria Jose De Miguel Luken, et al.European Journal of Cancer (Oxford, England : 1990)|March 9, 2017
Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trialsAngela George, Rebecca Kristeleit, Saeed Rafii, et al.Clinical Therapeutics|October 18, 2016
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label StudiesLuc Dirix, Helen Swaisland, Henk M W Verheul, et al.Pageof 5